Ignite Creation Date:
2025-12-24 @ 10:10 PM
Ignite Modification Date:
2026-01-01 @ 5:06 PM
Study NCT ID:
NCT05996835
Status:
RECRUITING
Last Update Posted:
2025-12-23
First Post:
2023-08-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D018805', 'term': 'Sepsis'}, {'id': 'D058186', 'term': 'Acute Kidney Injury'}], 'ancestors': [{'id': 'D007239', 'term': 'Infections'}, {'id': 'D018746', 'term': 'Systemic Inflammatory Response Syndrome'}, {'id': 'D007249', 'term': 'Inflammation'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D051437', 'term': 'Renal Insufficiency'}, {'id': 'D007674', 'term': 'Kidney Diseases'}, {'id': 'D014570', 'term': 'Urologic Diseases'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 320}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2024-01-18', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2026-04-21', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-22', 'studyFirstSubmitDate': '2023-08-10', 'studyFirstSubmitQcDate': '2023-08-10', 'lastUpdatePostDateStruct': {'date': '2025-12-23', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2023-08-18', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-02-02', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Average of area under the time-corrected creatinine clearance curve (AUC1-8)', 'timeFrame': 'Day 1 to Day 8', 'description': 'The weighted average of area under the time-corrected endogenous creatinine clearance curve.\n\nUrine volume, urinary creatinine, and the serum creatinine measurements will be used for calculation. Day 1-8 measurements will be included.'}], 'secondaryOutcomes': [{'measure': 'Percentage of participants with major adverse kidney events (MAKE)', 'timeFrame': 'Day 1 to Day 90', 'description': 'A binary composite endpoint of major adverse kidney events (MAKE) including death, use of Renal Replacement Therapy (RRT) and ≥25% reduction from reference in estimated Glomular Filtration Rate (eGFR) at Day 90.'}, {'measure': 'Area under the time-corrected endogenous serum creatinine curve for Day 1 to Day 14 and Day 1 to Day 30.', 'timeFrame': 'Day 1 to Day 14 and Day 1 to Day 30', 'description': 'The weighted average of area under the time-corrected endogenous serum creatinine curve from Day 1 to Day 14 and Day 1 to Day 30.'}, {'measure': 'Area under the time-corrected endogenous serum cystatin C curve for Day 1 to Day 14 and Day 1 to Day 30', 'timeFrame': 'Day 1 to Day 14 and Day 1 to Day 30', 'description': 'The weighted average of area under the time-corrected endogenous serum cystatin-C curve from Day 1 to Day 14 and Day 1 to Day 30.'}, {'measure': 'Area under the time-corrected creatinine clearance curve (AUC5-14)', 'timeFrame': 'Day 5 to Day 14', 'description': 'The weighted average of area under the time-corrected endogenous creatinine clearance curve.\n\nUrine volume, urinary creatinine, and the serum creatinine measurements will be used for calculation. Day 5-14 measurements will be included.'}, {'measure': 'Percentage of participants who had renal replacement therapy (RRT) from Day 1 to Day 90', 'timeFrame': 'Day 1 to Day 90', 'description': 'Use of RRT at any time during the treatment period will be reported.'}, {'measure': 'Percentage of participants with RRT dependency at Day 90', 'timeFrame': 'Day 90', 'description': 'Use of RRT dependency at Day 90 will be reported'}, {'measure': 'Number of days participants alive and free of RRT from Day 1 to Day 90', 'timeFrame': 'Day 1 to Day 90', 'description': 'Participants who are alive and free of RRT, defined as any participant receiving any form of RRT, will be reported.'}, {'measure': 'Change in Kidney disease improving global outcomes (KDIGO) score from Baseline to Day 14', 'timeFrame': '14 Days', 'description': 'The KDIGO classification system stages AKI into three levels based on serum creatinine elevation in parallel with degree and duration of oliguria. Participants are classified based on the worst finding (either serum creatinine or oliguria). The stages range from 1-3, with higher scores indicating the most severe stage of AKI.'}, {'measure': 'Percentage of participants with ≥25% reduction in eGFR at Day 90', 'timeFrame': '90 Days', 'description': 'Percentage of participants with ≥ 25% reduction from reference to Day 90.'}, {'measure': 'Mean change of sequential organ failure assessment score (SOFA) from baseline to Day 30', 'timeFrame': '30 Days', 'description': 'The SOFA score was developed to assess the acute morbidity of critical illness at a population level. The score is routinely calculated on admission to ICU and at each 24-hour period that follows. It is composed of six criteria which reflect the function of a specific organ system (respiratory, cardiovascular, renal, neurological, hepatic and hematological) and allocates a score of 0-4.\n\nScores ranges from 0-24, with higher scores indicating greater dysfunction.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Sepsis', 'acute kidney injury', 'anti-inflammatory', 'immunosuppression', 'intensive care unit'], 'conditions': ['Acute Kidney Injury Due to Sepsis']}, 'descriptionModule': {'briefSummary': 'The purpose of this Ph2b study is to characterize the dose-response relationship and to evaluate the safety and efficacy of three different single doses of TIN816 in hospitalized adult participants in an intensive care setting with a diagnosis of sepsis-associated acute kidney injury (SA-AKI).', 'detailedDescription': 'This is a multicenter, randomized, double-blind, placebo-controlled, four-arm, parallel-group, dose-finding phase 2b study. The study will enroll hospitalized adult participants with a diagnosis of sepsis and acute kidney injury (AKI). The study consists of a screening period (24-48 hours), a treatment period (Day 1), and post-treatment period (Day 2 to 90). Screening will take place during hospitalization in ICU (or intermediate care unit/HDU) where potential participants will undergo screening to assess the presence of sepsis and AKI. At Treatment Day 1, participants who meet eligibility criteria at screening and baseline will be randomized in a 3:1:1:3 ratio to receive a one-time treatment of TIN816 or placebo by intravenous infusion in a participant and investigator-blinded fashion. Treatment Day 1 is followed by a 90-day post-treatment period for safety and efficacy assessments. An interim analysis (IA) is planned when approximately 120 participants complete Day 30 visit. A final analysis will be performed after all participants have completed Day 90.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '85 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Signed informed consent must be obtained in accordance with local regulations.\n2. ≥ 18 to ≤ 85 years of age\n3. Admitted to ICU or intermediate care unit/ high dependency care unit (HDU)\n4. Diagnosis of sepsis according to criteria defined by The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) based on:\n\n * Suspected or confirmed infection AND\n * Acute increase of SOFA score of 2 or more (excluding renal component). The baseline SOFA score should be assumed to be zero unless the participant is known to have pre-existing (acute or chronic) organ dysfunction before the onset of infection\n5. Diagnosis of AKI Stage 1 or greater per the following criterion at randomization:\n\nAn absolute increase in serum or plasma creatinine by ≥ 0.3 mg/dL (≥ 26.5 µmol/L) within 48 hours or presumed to have occurred in the previous 48 hours as compared to the reference serum creatinine.\n\n* For participants with hospital-acquired AKI, a stable serum creatinine obtained in the hospital prior to AKI diagnosis should be used as the reference serum creatinine.\n* For participants presenting from community, the reference serum creatinine should be estimated using the following order of preference:\n\n 1. The most recent value within 3 months of the hospital admission. If not available:\n 2. The most recent value between 3 and 12 months prior to hospital admission. If not available:\n 3. At hospital admission\n\nExclusion criteria\n\n1. Not expected to survive for 24 hours\n2. Not expected to survive for 30 days due to medical conditions other than SA-AKI\n3. History of CKD with a documented estimated GFR \\<30 mL/min prior to admission to hospital\n4. eGFR \\<45mL/min at admission without any other reference serum eGFR within last 12-months\n5. Receiving RRT or a decision has been made to initiate RRT within 24 hours after randomization\n6. Weight is less than 40 kg or more than 125 kg.\n7. Limitations to the use of mechanical ventilation, RRT or vasopressors/inotropes (N.B. limitations on Cardiopulmonary resuscitation (CPR)e.g., do-not-resuscitate orders are not an exclusion criterion unless associated with likely poor outcome in next 24 hours)\n8. Sepsis diagnosis according to sepsis inclusion criteria for a period longer than 72 hours prior to ICU admission\n9. AKI diagnosis according to AKI inclusion criteria over 48 hours after admission to ICU\n10. Inability to administer study drug within 24 hours of diagnosis of AKI according to AKI inclusion criteria\n11. Presence of AKI, in the Investigator's opinion, as suggested by clinical manifestation, e.g., prolonged oliguria or severe renal dysfunction on admission without a history of CKD, for a period longer than 24 hours prior to study drug administration\n12. Evidence of recovery from AKI based on the investigator's clinical judgement prior to randomization\n13. AKI is most likely attributable to other causes than sepsis, such as nephrotoxic drugs (Non-steroidal anti-inflammatory drugs (NSAIDs), contrast, aminoglycosides, etc.) or renal perfusion-related (acute abdominal aortic aneurysm, dissection, renal artery stenosis), urinary obstruction\n14. Documented (biopsy proven) or suspected history of acute or sub-acute kidney diseases such as rapidly progressive glomerular nephritis (RPGN) and acute interstitial nephritis (AIN)\n15. Patients who are post-nephrectomy\n16. Patients with permanent incapacitation\n17. Patients who are thrombocytopenic at screening (platelet count \\<50,000 per microliter) who have active/uncontrolled bleeding or who present current or past conditions indicating high risk for bleeding in the opinion of the investigator (e.g. coagulopathies, previous history of major non-traumatic bleeding etc.)\n18. Immunosuppressed patients\n\n * History of immunodeficiency diseases\n * Receiving immunosuppressant treatment or on chronic high doses (high-dose therapy exceeding 2 weeks of treatment) of steroids equivalent to prednisone/prednisolone 0.5 mg/kg/day, including solid organ transplant patients. Patients with septic shock treated with corticosteroids (as per the Surviving Sepsis Guidelines) can be included.\n19. Patients with known or presumed latent or active TB based on clinical history or imaging e.g. patients on TB preventive therapy or close/household contacts of pulmonary TB patients\n20. Known active hepatitis B or C infection (clinical diagnosis or positive infection serology), or advanced chronic liver disease, confirmed by a Child-Pugh score of 10-15 (Class C)\n21. Acute pancreatitis with no established source of infection\n22. Active hematological malignancy (previous hematological malignancies that are not actively treated are allowable)\n23. Burns requiring ICU treatment\n24. Sepsis attributed to confirmed COVID-19\n25. Use of other investigational drugs within 5 half-lives of enrollment, within 30 days (e.g., small molecules) or until the expected pharmacodynamic effect has returned to baseline (e.g., biologics), whichever is longer; or longer if required by local regulations\n26. History of hypersensitivity to the study treatment or its excipients or to drugs of similar chemical classes\n27. Any medical conditions that could significantly increase risk of participants' safety by participating in this study according to investigator's judgement\n28. Women with a positive pregnancy test, pregnancy or breast feeding\n29. Women of childbearing potential, unless they are using highly effective methods of contraception for the entire duration of the trial."}, 'identificationModule': {'nctId': 'NCT05996835', 'acronym': 'CLEAR-AKI', 'briefTitle': 'Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Novartis'}, 'officialTitle': 'A Multicenter, Randomized, Double-blind, Placebo-controlled, Four-arm, Parallel-group, Dose-finding Phase 2b Study to Investigate the Safety and Efficacy of TIN816 Via a Single Intravenous Infusion in the Treatment of Participants With Sepsis-associated Acute Kidney Injury (CLEAR-AKI)', 'orgStudyIdInfo': {'id': 'CTIN816B12202'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'TIN816 Dose A', 'description': 'Administered as a one time intravenous dose', 'interventionNames': ['Biological: TIN816 70 mg lyophilisate powder']}, {'type': 'EXPERIMENTAL', 'label': 'TIN816 Dose B', 'description': 'Administered as a one time intravenous dose', 'interventionNames': ['Biological: TIN816 70 mg lyophilisate powder']}, {'type': 'EXPERIMENTAL', 'label': 'TIN816 Dose C', 'description': 'Administered as a one time intravenous dose', 'interventionNames': ['Biological: TIN816 70 mg lyophilisate powder']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': '0.9% sterile saline administered as a one time intravenous dose', 'interventionNames': ['Other: Placebo']}], 'interventions': [{'name': 'TIN816 70 mg lyophilisate powder', 'type': 'BIOLOGICAL', 'description': 'Immunotherapy Recombinant human CD39 enzyme', 'armGroupLabels': ['TIN816 Dose A', 'TIN816 Dose B', 'TIN816 Dose C']}, {'name': 'Placebo', 'type': 'OTHER', 'description': '0.9% sterile saline solution', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '35233', 'city': 'Birmingham', 'state': 'Alabama', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Aleena Asif', 'role': 'CONTACT', 'email': 'aleenaasif@uabmc.edu'}, {'name': 'Javier Neyra', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University Of Alabama', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'zip': '94143-0116', 'city': 'San Francisco', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Aqsa Khan', 'role': 'CONTACT', 'email': 'aqsa.khan@ucsf.edu', 'phone': '+1 415 476 2091'}, {'name': 'Matthieu Legrand', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'UC San Francisco Medical Center', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'zip': '94305 5152', 'city': 'Stanford', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Kelley Logan', 'role': 'CONTACT', 'email': 'kalogan@stanford.edu'}, {'name': 'Ronald Pearl', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Stanford Healthcare', 'geoPoint': {'lat': 37.42411, 'lon': -122.16608}}, {'zip': '30097', 'city': 'Johns Creek', 'state': 'Georgia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Amy Anderson', 'role': 'CONTACT', 'email': 'amy.anderson@emory.edu'}, {'name': 'Venu Velagapudi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Emory Johns Creek Hospital', 'geoPoint': {'lat': 34.02893, 'lon': -84.19858}}, {'zip': '60611', 'city': 'Evanston', 'state': 'Illinois', 'status': 'COMPLETED', 'country': 'United States', 'facility': 'Northwestern Memorial Hospital', 'geoPoint': {'lat': 42.04114, 'lon': -87.69006}}, {'zip': '60077', 'city': 'Glenview', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Catherine Futoransky', 'role': 'CONTACT', 'email': 'cfutoransky@northshore.org', 'phone': '+1 847 663 6814'}, {'name': 'Ben Margolis', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Endeavor Health', 'geoPoint': {'lat': 42.06975, 'lon': -87.78784}}, {'zip': '52242', 'city': 'Iowa City', 'state': 'Iowa', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Mc Lean Sunderland', 'role': 'CONTACT', 'email': 'mclean-sunderland@uiowa.edu', 'phone': '+1 319 356 1826'}, {'name': 'Benjamin Griffin', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Univ Of Iowa Hospitals And Clinics', 'geoPoint': {'lat': 41.66113, 'lon': -91.53017}}, {'zip': '52242', 'city': 'Iowa City', 'state': 'Iowa', 'status': 'WITHDRAWN', 'country': 'United States', 'facility': 'Univ Of Iowa Hospitals And Clinics', 'geoPoint': {'lat': 41.66113, 'lon': -91.53017}}, {'zip': '02114', 'city': 'Boston', 'state': 'Massachusetts', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Sydney Olafsen', 'role': 'CONTACT', 'email': 'solafsen@mgh.harvard.edu', 'phone': '+1 617 724 4000'}, {'name': 'Kathryn Hibbert', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Massachusetts General Hospital', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '02215', 'city': 'Boston', 'state': 'Massachusetts', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Carlo Ottanelli', 'role': 'CONTACT', 'email': 'cottanel@bidmc.harvard.edu'}, {'name': 'Tatyana Shvilkina', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Beth Israel Deaconess Med Center', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '01805', 'city': 'Burlington', 'state': 'Massachusetts', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Caroline Schissel', 'role': 'CONTACT', 'email': 'caroline.schissel@lahey.org', 'phone': '+1 781 744 3874'}, {'name': 'Christopher Hansen', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Lahey Hospital and Medical Center', 'geoPoint': {'lat': 42.50482, 'lon': -71.19561}}, {'zip': '01199', 'city': 'Springfield', 'state': 'Massachusetts', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Lesley Desouza', 'role': 'CONTACT', 'email': 'Lesley.desouza@baystatehealth.org', 'phone': '+1 413 784 5439'}, {'name': 'Mark Tidswell', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Baystate Medical Center', 'geoPoint': {'lat': 42.10148, 'lon': -72.58981}}, {'zip': '48202-2689', 'city': 'Detroit', 'state': 'Michigan', 'status': 'WITHDRAWN', 'country': 'United States', 'facility': 'Henry Ford Hospital', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'zip': '55905', 'city': 'Rochester', 'state': 'Minnesota', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Mitchell Strand', 'role': 'CONTACT', 'email': 'Strand.Mitchell@mayo.edu'}, {'name': 'Kianoush Kashani', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Mayo Clinic Rochester', 'geoPoint': {'lat': 44.02163, 'lon': -92.4699}}, {'zip': '10461', 'city': 'The Bronx', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Brenda Lopez', 'role': 'CONTACT', 'email': 'brenda.lopez@einsteinmed.edu', 'phone': '+1 718 904 2321'}, {'name': 'Luke Andrea', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Montefiore Medical Center', 'geoPoint': {'lat': 40.84985, 'lon': -73.86641}}, {'zip': '10467', 'city': 'The Bronx', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Daniel Ceusters', 'role': 'CONTACT', 'email': 'dceuster@montefiore.org', 'phone': '+1 718 920 2776'}, {'name': 'Ari Moskowitz', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Montefiore Medical Center', 'geoPoint': {'lat': 40.84985, 'lon': -73.86641}}, {'zip': '27157-1071', 'city': 'Winston-Salem', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Tanmay Sura', 'role': 'CONTACT', 'email': 'tsura@wakehealth.edu', 'phone': '+1 513 658 5866'}, {'name': 'Ashish Khanna', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Wake Forest Univ School of Medicine', 'geoPoint': {'lat': 36.09986, 'lon': -80.24422}}, {'zip': '43210', 'city': 'Columbus', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Sarah Karow', 'role': 'CONTACT', 'email': 'Sarah.Karow@osumc.edu'}, {'name': 'Matthew Exline', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Ohio State University Medical Center', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '97330', 'city': 'Corvallis', 'state': 'Oregon', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Kristen Moylan', 'role': 'CONTACT', 'email': 'kmoylan@samhealth.org', 'phone': '+1 541 768 5202'}, {'name': 'Brian Delmonaco', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Good Samaritan Hospital', 'geoPoint': {'lat': 44.56457, 'lon': -123.26204}}, {'zip': '19140', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Ellen Bedenko', 'role': 'CONTACT', 'email': 'ellen.bedenko@temple.edu', 'phone': '+1 215 707 2230'}, {'name': 'Avrum Gillespie', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Temple University', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '15213', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Tina Vita', 'role': 'CONTACT', 'email': 'vitatm@upmc.edu', 'phone': '+1 412 391 8760'}, {'name': 'Raghavan Murugan', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'U Of Pittsburgh Med Ctr', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '75246', 'city': 'Dallas', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Daniela Gonzalez', 'role': 'CONTACT', 'email': 'Daniela.Gonzalez1@BSWHealth.org'}, {'name': 'Ankit Mehta', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Baylor Scott and White', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '84107', 'city': 'Murray', 'state': 'Utah', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Jose Romero', 'role': 'CONTACT', 'email': 'Jose.Romero1@imail.org', 'phone': '+1 801 507 9333'}, {'name': 'Ithan Peltan', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Utah Intermountain Medical Center', 'geoPoint': {'lat': 40.66689, 'lon': -111.88799}}, {'zip': '22042', 'city': 'Falls Church', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Kedir Seid', 'role': 'CONTACT', 'email': 'Kedir.Seid@inova.org', 'phone': '+1 703 698 3580'}, {'name': 'Markos Kashiouris', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Inova Fairfax Hospital', 'geoPoint': {'lat': 38.88233, 'lon': -77.17109}}, {'zip': '23298', 'city': 'Richmond', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Shawn Fenner', 'role': 'CONTACT', 'email': 'shawn.fenner@vcuhealth.org'}, {'name': 'Anna Vinnikova', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Virginia Commonwealth University', 'geoPoint': {'lat': 37.55376, 'lon': -77.46026}}, {'zip': '99204', 'city': 'Spokane', 'state': 'Washington', 'status': 'WITHDRAWN', 'country': 'United States', 'facility': 'Providence Med Resch Center and Chindren Hosp', 'geoPoint': {'lat': 47.65966, 'lon': -117.42908}}, {'zip': 'C1118AAT', 'city': 'CABA', 'state': 'Buenos Aires', 'status': 'RECRUITING', 'country': 'Argentina', 'facility': 'Novartis Investigative Site'}, {'zip': 'B1629AHJ', 'city': 'Pilar', 'state': 'Buenos Aires', 'status': 'RECRUITING', 'country': 'Argentina', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': -34.45867, 'lon': -58.91398}}, {'zip': 'C1181ACH', 'city': 'CABA', 'status': 'RECRUITING', 'country': 'Argentina', 'facility': 'Novartis Investigative Site'}, {'zip': 'S3000EPV', 'city': 'Santa Fe', 'status': 'RECRUITING', 'country': 'Argentina', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': -31.64881, 'lon': -60.70868}}, {'zip': '4029', 'city': 'Herston', 'state': 'Queensland', 'status': 'RECRUITING', 'country': 'Australia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': -27.44453, 'lon': 153.01852}}, {'zip': '3084', 'city': 'Heidelberg', 'state': 'Victoria', 'status': 'RECRUITING', 'country': 'Australia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': -37.75, 'lon': 145.06667}}, {'zip': '6020', 'city': 'Innsbruck', 'state': 'Tyrol', 'status': 'RECRUITING', 'country': 'Austria', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.26266, 'lon': 11.39454}}, {'zip': '3600', 'city': 'Genk', 'state': 'Limburg', 'status': 'RECRUITING', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.965, 'lon': 5.50082}}, {'zip': '1200', 'city': 'Brussels', 'status': 'RECRUITING', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'zip': '9000', 'city': 'Ghent', 'status': 'RECRUITING', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.05, 'lon': 3.71667}}, {'zip': '1340', 'city': 'Ottignies', 'status': 'RECRUITING', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.66535, 'lon': 4.56679}}, {'zip': '70390-140', 'city': 'Brasília', 'state': 'Federal District', 'status': 'RECRUITING', 'country': 'Brazil', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': -15.77972, 'lon': -47.92972}}, {'zip': '80010 030', 'city': 'Curitiba', 'state': 'Paraná', 'status': 'RECRUITING', 'country': 'Brazil', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': -25.42778, 'lon': -49.27306}}, {'zip': '09090-790', 'city': 'Santo André', 'state': 'São Paulo', 'status': 'RECRUITING', 'country': 'Brazil', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': -23.66389, 'lon': -46.53833}}, {'zip': '01327 001', 'city': 'São Paulo', 'state': 'São Paulo', 'status': 'RECRUITING', 'country': 'Brazil', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': '40323-010', 'city': 'Salvador', 'status': 'RECRUITING', 'country': 'Brazil', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': -12.97563, 'lon': -38.49096}}, {'zip': 'V6Z 1Y6', 'city': 'Vancouver', 'state': 'British Columbia', 'status': 'RECRUITING', 'country': 'Canada', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.24966, 'lon': -123.11934}}, {'zip': 'K7L 2V7', 'city': 'Kingston', 'state': 'Ontario', 'status': 'WITHDRAWN', 'country': 'Canada', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 44.22976, 'lon': -76.48098}}, {'zip': 'H2W 1T8', 'city': 'Montreal', 'state': 'Quebec', 'status': 'RECRUITING', 'country': 'Canada', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'zip': 'H4J 1C5', 'city': 'Montreal', 'state': 'Quebec', 'status': 'RECRUITING', 'country': 'Canada', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'zip': 'G1V 4G5', 'city': 'Québec', 'state': 'Quebec', 'status': 'RECRUITING', 'country': 'Canada', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 46.81228, 'lon': -71.21454}}, {'zip': '050011', 'city': 'Shijiazhuang', 'state': 'Hebei', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 38.04139, 'lon': 114.47861}}, {'zip': '450003', 'city': 'Zhengzhou', 'state': 'Henan', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}, {'zip': '310014', 'city': 'Hangzhou', 'state': 'Zhejiang', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'zip': '100730', 'city': 'Beijing', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '510260', 'city': 'Guangzhou', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'zip': '430022', 'city': 'Wuhan', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}}, {'zip': '13915', 'city': 'Marseille', 'state': 'Bouches Du Rhone', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 43.29695, 'lon': 5.38107}}, {'zip': '49933', 'city': 'Angers', 'state': 'France', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.47156, 'lon': -0.55202}}, {'zip': '87000', 'city': 'Limoges', 'state': 'Haute Vienne', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.83362, 'lon': 1.24759}}, {'zip': '95107', 'city': 'Argenteuil', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.94788, 'lon': 2.24744}}, {'zip': '92380', 'city': 'Garches', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.84226, 'lon': 2.18232}}, {'zip': '94275', 'city': 'Le Kremlin-Bicêtre', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.81471, 'lon': 2.36073}}, {'zip': '44093', 'city': 'Nantes', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.21725, 'lon': -1.55336}}, {'zip': '75010', 'city': 'Paris', 'status': 'WITHDRAWN', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '33604', 'city': 'Pessac', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 44.80565, 'lon': -0.6324}}, {'zip': '67091', 'city': 'Strasbourg', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.58392, 'lon': 7.74553}}, {'zip': '31054', 'city': 'Toulouse', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'zip': '70376', 'city': 'Stuttgart', 'state': 'Baden-Wurttemberg', 'status': 'RECRUITING', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.78232, 'lon': 9.17702}}, {'zip': '81377', 'city': 'Munich', 'state': 'Bavaria', 'status': 'RECRUITING', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.13743, 'lon': 11.57549}}, {'zip': '60590', 'city': 'Frankfurt am Main', 'state': 'Hesse', 'status': 'RECRUITING', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.11552, 'lon': 8.68417}}, {'zip': '07740', 'city': 'Jena', 'state': 'Thuringia', 'status': 'RECRUITING', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.92878, 'lon': 11.5899}}, {'zip': '45147', 'city': 'Essen', 'status': 'RECRUITING', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.45657, 'lon': 7.01228}}, {'zip': '24105', 'city': 'Kiel', 'status': 'RECRUITING', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 54.32133, 'lon': 10.13489}}, {'zip': '48149', 'city': 'Münster', 'status': 'RECRUITING', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.96236, 'lon': 7.62571}}, {'zip': '4032', 'city': 'Debrecen', 'state': 'Hajdu Bihar Megye', 'status': 'RECRUITING', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.53167, 'lon': 21.62444}}, {'zip': 'H-1097', 'city': 'Budapest', 'status': 'RECRUITING', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': 'H-9024', 'city': 'Győr', 'status': 'RECRUITING', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.68333, 'lon': 17.63512}}, {'zip': 'H-8000', 'city': 'Székesfehérvár', 'status': 'RECRUITING', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.18995, 'lon': 18.41034}}, {'zip': '380060', 'city': 'Ahmedabad', 'state': 'Gujarat', 'status': 'RECRUITING', 'country': 'India', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 23.02579, 'lon': 72.58727}}, {'zip': '590010', 'city': 'Belagavi', 'state': 'Karnataka', 'status': 'RECRUITING', 'country': 'India', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 15.85212, 'lon': 74.50447}}, {'zip': '411001', 'city': 'Pune', 'state': 'Maharashtra', 'status': 'RECRUITING', 'country': 'India', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 18.51957, 'lon': 73.85535}}, {'zip': '110001', 'city': 'New Delhi', 'state': 'National Capital Territory of Delhi', 'status': 'RECRUITING', 'country': 'India', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 28.62137, 'lon': 77.2148}}, {'zip': '500034', 'city': 'Hyderabad', 'state': 'Telangana', 'status': 'RECRUITING', 'country': 'India', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 17.38405, 'lon': 78.45636}}, {'zip': '40138', 'city': 'Bologna', 'state': 'BO', 'status': 'RECRUITING', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 44.49381, 'lon': 11.33875}}, {'zip': '20100', 'city': 'Milan', 'state': 'MI', 'status': 'RECRUITING', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '20162', 'city': 'Milan', 'state': 'MI', 'status': 'RECRUITING', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '20089', 'city': 'Rozzano', 'state': 'MI', 'status': 'RECRUITING', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.38193, 'lon': 9.1559}}, {'zip': '35128', 'city': 'Padua', 'state': 'PD', 'status': 'RECRUITING', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.40797, 'lon': 11.88586}}, {'zip': '06129', 'city': 'Perugia', 'state': 'PG', 'status': 'WITHDRAWN', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 43.1122, 'lon': 12.38878}}, {'zip': '00168', 'city': 'Roma', 'state': 'RM', 'status': 'RECRUITING', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}, {'zip': '80131', 'city': 'Napoli', 'status': 'RECRUITING', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 40.87618, 'lon': 14.5195}}, {'zip': '296-8602', 'city': 'Kamogawa', 'state': 'Chiba', 'status': 'COMPLETED', 'country': 'Japan', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 35.0969, 'lon': 140.1003}}, {'zip': '078 8510', 'city': 'Asahikawa', 'state': 'Hokkaido', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 43.77063, 'lon': 142.36489}}, {'zip': '245-8575', 'city': 'Yokohama', 'state': 'Kanagawa', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 35.43333, 'lon': 139.65}}, {'zip': '860-0008', 'city': 'Kumamoto', 'state': 'Kumamoto', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 32.80589, 'lon': 130.69181}}, {'zip': '5988577', 'city': 'Izumisano', 'state': 'Osaka', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 34.41667, 'lon': 135.31667}}, {'zip': '5340021', 'city': 'Osaka', 'state': 'Osaka', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 34.69379, 'lon': 135.50107}}, {'zip': '843-0393', 'city': 'Ureshino', 'state': 'Saga-ken', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'Japan', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 33.13525, 'lon': 130.05718}}, {'zip': '693-8555', 'city': 'Izumo', 'state': 'Shimane', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 35.36667, 'lon': 132.76667}}, {'zip': '193-0998', 'city': 'Hachiōji', 'state': 'Tokyo', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 35.65583, 'lon': 139.32389}}, {'zip': '1738610', 'city': 'Itabashi-ku', 'state': 'Tokyo', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'Novartis Investigative Site'}, {'zip': '8128582', 'city': 'Fukuoka', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 33.6, 'lon': 130.41667}}, {'zip': '862-8505', 'city': 'Kumamoto', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 32.80589, 'lon': 130.69181}}, {'zip': '0002', 'city': 'Pretoria', 'status': 'RECRUITING', 'country': 'South Africa', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': -25.74486, 'lon': 28.18783}}, {'zip': '15706', 'city': 'Santiago Compostela', 'state': 'A Coruna', 'status': 'WITHDRAWN', 'country': 'Spain', 'facility': 'Novartis Investigative Site'}, {'zip': '08907', 'city': "L'Hospitalet de Llobregat", 'state': 'Barcelona', 'status': 'WITHDRAWN', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.35967, 'lon': 2.10028}}, {'zip': '08208', 'city': 'Sabadell', 'state': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.54329, 'lon': 2.10942}}, {'zip': '11407', 'city': 'Jerez de la Frontera', 'state': 'Cadiz', 'status': 'WITHDRAWN', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 36.68645, 'lon': -6.13606}}, {'zip': '08221', 'city': 'Terrassa', 'state': 'Catalonia', 'status': 'WITHDRAWN', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.56667, 'lon': 2.01667}}, {'zip': '08035', 'city': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '08041', 'city': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '14004', 'city': 'Córdoba', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 37.89155, 'lon': -4.77275}}, {'zip': '28040', 'city': 'Madrid', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28041', 'city': 'Madrid', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '46026', 'city': 'Valencia', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'zip': '10330', 'city': 'Bangkok', 'status': 'RECRUITING', 'country': 'Thailand', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}, {'zip': '10400', 'city': 'Bangkok', 'status': 'RECRUITING', 'country': 'Thailand', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}, {'zip': '10700', 'city': 'Bangkok', 'status': 'RECRUITING', 'country': 'Thailand', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}, {'zip': '50200', 'city': 'Chiang Mai', 'status': 'RECRUITING', 'country': 'Thailand', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 18.79038, 'lon': 98.98468}}, {'zip': '34093', 'city': 'Istanbul', 'state': 'Fatih', 'status': 'WITHDRAWN', 'country': 'Turkey (Türkiye)', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'zip': '06230', 'city': 'Ankara', 'state': 'Sihhiye-Altindag', 'status': 'WITHDRAWN', 'country': 'Turkey (Türkiye)', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 39.91987, 'lon': 32.85427}}, {'zip': 'GU2 7XX', 'city': 'Guildford', 'state': 'Surrey', 'status': 'WITHDRAWN', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.23536, 'lon': -0.57427}}, {'zip': 'B15 2TH', 'city': 'Birmingham', 'state': 'West Midlands', 'status': 'RECRUITING', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.48142, 'lon': -1.89983}}, {'zip': 'BS2 8HW', 'city': 'Bristol', 'status': 'WITHDRAWN', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.45523, 'lon': -2.59665}}, {'zip': 'SE1 7EH', 'city': 'London', 'status': 'RECRUITING', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}], 'centralContacts': [{'name': 'Novartis Pharmaceuticals', 'role': 'CONTACT', 'email': 'novartis.email@novartis.com', 'phone': '1-888-669-6682'}, {'name': 'Novartis Pharmaceuticals', 'role': 'CONTACT', 'phone': '+41613241111'}], 'overallOfficials': [{'name': 'Novartis Pharmaceuticals', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Novartis Pharmaceuticals'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.\n\nThis trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Novartis Pharmaceuticals', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}